Mycapssa Patent Expiration

Mycapssa is a drug owned by Chiesi Farmaceutici Spa. It is protected by 14 US drug patents filed from 2020 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 28, 2040. Details of Mycapssa's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11141457 Oral octreotide therapy and contraceptive methods
Dec, 2040

(16 years from now)

Active
US11890316 Oral octreotide therapy and contraceptive methods
Dec, 2040

(16 years from now)

Active
US10238709 Method of treating diseases
Feb, 2036

(11 years from now)

Active
US11510963 Method of treating diseases
Feb, 2036

(11 years from now)

Active
US11052126 Method of treating diseases
Feb, 2036

(11 years from now)

Active
US11857595 Method of treating diseases
Feb, 2036

(11 years from now)

Active
US11338011 Method of treating diseases
Feb, 2036

(11 years from now)

Active
US10695397 Method of treating diseases
Feb, 2036

(11 years from now)

Active
US8535695 Pharmaceutical compositions and related methods of delivery
Sep, 2029

(4 years from now)

Active
US11986529 Pharmaceutical compositions and related methods of delivery
Sep, 2029

(4 years from now)

Active
US11969471 Pharmaceutical compositions and related methods of delivery
Sep, 2029

(4 years from now)

Active
US8329198 Pharmaceutical compositions and related methods of delivery
Sep, 2029

(4 years from now)

Active
US9265812 Pharmaceutical compositions and related methods of delivery
Sep, 2029

(4 years from now)

Active
US9566246 Pharmaceutical compositions and related methods of delivery
Sep, 2029

(4 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Mycapssa's patents.

Given below is the list of recent legal activities going on the following patents of Mycapssa.

Activity Date Patent Number
Patent litigations
Electronic Review 07 Jun, 2024 US11969471
Payment of Maintenance Fee, 12th Year, Large Entity 03 Jun, 2024 US8329198
Mail O.P. Petition Decision 06 May, 2024 US11969471
Email Notification 06 May, 2024 US11969471
Mail-Record Petition Decision of Granted to Make Entity Status large 02 May, 2024 US11969471
Record Petition Decision of Granted to Make Entity Status large 01 May, 2024 US11969471
Mail Patent eGrant Notification 30 Apr, 2024 US11969471
O.P. Petition Decision 30 Apr, 2024 US11969471
Patent eGrant Notification 30 Apr, 2024 US11969471
Recordation of Patent eGrant 30 Apr, 2024 US11969471


FDA has granted several exclusivities to Mycapssa. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Mycapssa, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Mycapssa.

Exclusivity Information

Mycapssa holds 2 exclusivities out of which 1 have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Mycapssa's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 26, 2023
Orphan Drug Exclusivity(ODE-474) Jun 26, 2027

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Mycapssa is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Mycapssa's family patents as well as insights into ongoing legal events on those patents.

Mycapssa's Family Patents

Mycapssa has patent protection in a total of 26 countries. It's US patent count contributes only to 32.0% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Mycapssa.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Mycapssa's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 28, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Mycapssa Generics:

Octreotide Acetate is the generic name for the brand Mycapssa. 11 different companies have already filed for the generic of Mycapssa, with Sun Pharm Inds having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Mycapssa's generic

Alternative Brands for Mycapssa

Mycapssa which is used for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide., has several other brand drugs using the same active ingredient (Octreotide Acetate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Novartis
Sandostatin
Sandostatin Lar
Sun Pharm
Bynfezia Pen


Apart from brand drugs containing the same ingredient, some generics have also been filed for Octreotide Acetate, Mycapssa's active ingredient. Check the complete list of approved generic manufacturers for Mycapssa





About Mycapssa

Mycapssa is a drug owned by Chiesi Farmaceutici Spa. It is used for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. Mycapssa uses Octreotide Acetate as an active ingredient. Mycapssa was launched by Chiesi in 2020.

Approval Date:

Mycapssa was approved by FDA for market use on 26 June, 2020.

Active Ingredient:

Mycapssa uses Octreotide Acetate as the active ingredient. Check out other Drugs and Companies using Octreotide Acetate ingredient

Treatment:

Mycapssa is used for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

Dosage:

Mycapssa is available in capsule, delayed release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 20MG BASE CAPSULE, DELAYED RELEASE Prescription ORAL